Literature DB >> 12530094

Glutathione S-transferase (GSTM1 and GSTT1)-dependent risk for colorectal cancer.

N Laso1, M J Lafuente, S Mas, M Trias, C Ascaso, R Molina, A Ballesta, F Rodriguez, A Lafuente.   

Abstract

BACKGROUND: The deleted GSTT1 and GSTM1 genotypes (null genotypes) resulting in loss of transferase activity are found in 10-20% and 50-60% of the population, respectively. PATIENTS AND METHODS: The GSTT1- and GSTM1-dependent risk for sporadic colorectal cancer (CRC) was studied in 247 incident CRC cases and 296 hospital-based controls.
RESULTS: The GSTT1-null genotype was found to be 1.5 times more prevalent in CRC patients (17.4%) compared with controls (11.1%) (crude OR 1.6; p = 0.03). The GSTM1-null genotype was found to be equally prevalent in cases and controls (53%). Multivariate analysis showed a significant 1.7-fold risk for CRC associated with the GSTT1-null genotypes (p = 0.04) and this increased to 2.9 for smokers (p = 0.02).
CONCLUSION: This study provides evidence of gene-environment interaction and illustrates the importance of further research into the role of genetic susceptibility for CRC.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12530094

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  3 in total

1.  Polymorphism of glutathione S-transferase mu 1 and theta 1 genes and hepatocellular carcinoma in southern Guangxi, China.

Authors:  Zhuo-Lin Deng; Yi-Ping Wei; Yun Ma
Journal:  World J Gastroenterol       Date:  2005-01-14       Impact factor: 5.742

2.  An updating meta-analysis of the glutathione S-transferase T1 polymorphisms and colorectal cancer risk: a HuGE review.

Authors:  Cun Liao; Yunfei Cao; Liucheng Wu; Jiahao Huang; Feng Gao
Journal:  Int J Colorectal Dis       Date:  2009-10-02       Impact factor: 2.571

3.  Satisfaction survey with DNA cards method to collect genetic samples for pharmacogenetics studies.

Authors:  Jose M Vidal-Taboada; Mercedes Cucala; Sergio Mas Herrero; Amalia Lafuente; Albert Cobos
Journal:  BMC Med Genet       Date:  2006-05-08       Impact factor: 2.103

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.